Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 2,794,000 | 1,786,200 | 817,800 | 4,338,400 | 3,141,300 |
| Depreciation Amortization | 308,000 | 202,600 | 99,500 | 341,400 | 241,300 |
| Income taxes - deferred | -551,500 | -425,800 | -216,500 | -746,400 | -466,700 |
| Accounts receivable | -256,100 | 207,400 | 210,100 | 707,800 | 488,200 |
| Other Working Capital | -32,700 | 159,600 | 240,900 | -243,300 | -625,300 |
| Other Operating Activity | 1,242,600 | 460,000 | 215,800 | 617,000 | 516,200 |
| Operating Cash Flow | $3,504,300 | $2,390,000 | $1,367,600 | $5,014,900 | $3,295,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -2,454,900 | -2,209,600 | 43,400 | -1,937,400 | -331,900 |
| PPE Investments | -467,200 | -291,200 | -178,200 | -590,100 | -437,900 |
| Net Acquisitions | -51,100 | N/A | N/A | -230,300 | -230,300 |
| Purchase Sale Intangibles | -145,700 | -121,800 | -100,900 | -1,026,800 | -926,800 |
| Other Investing Activity | -145,700 | -121,800 | -100,900 | -1,026,800 | -926,800 |
| Investing Cash Flow | $-3,118,900 | $-2,622,600 | $-235,700 | $-3,784,600 | $-1,926,900 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 844,500 | 575,900 | 485,200 | 1,519,500 | 1,146,900 |
| Common Stock Repurchased | -2,188,500 | -1,512,600 | -807,700 | -2,528,500 | -1,908,300 |
| Financing Cash Flow | $-1,344,000 | $-936,700 | $-322,500 | $-1,009,000 | $-761,400 |
| Exchange Rate Effect | -600 | -400 | 0 | N/A | 0 |
| Beginning Cash Position | 3,119,400 | 3,119,400 | 3,119,400 | 2,898,100 | 2,898,100 |
| End Cash Position | 2,160,200 | 1,949,700 | 3,928,800 | 3,119,400 | 3,504,800 |
| Net Cash Flow | $-959,200 | $-1,169,700 | $809,400 | $221,300 | $606,700 |
| Free Cash Flow | |||||
| Operating Cash Flow | 3,504,300 | 2,390,000 | 1,367,600 | 5,014,900 | 3,295,000 |
| Capital Expenditure | -467,200 | -291,200 | -178,200 | -590,100 | -437,900 |
| Free Cash Flow | 3,037,100 | 2,098,800 | 1,189,400 | 4,424,800 | 2,857,100 |